Holen Sie sich die Stockscreener-App
4.36
7.82%
-0.37
Handel nachbörslich:
4.30
-0.06
-1.38%
Schlusskurs vom Vortag:
$4.73
Offen:
$4.73
24-Stunden-Volumen:
584.48K
Relative Volume:
0.41
Marktkapitalisierung:
$148.74M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.25M
KGV:
-3.7805
EPS:
-1.1533
Netto-Cashflow:
$-22.80M
1W Leistung:
-25.47%
1M Leistung:
-19.41%
6M Leistung:
-5.63%
1J Leistung:
+47.30%
1-Tages-Spanne:
$4.35
$4.85
1-Wochen-Bereich:
$4.35
$6.40
52-Wochen-Spanne:
$2.39
$20.71
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Firmenname
Sagimet Biosciences Inc
Sektor
Branche
Telefon
(650) 561-8600
Adresse
155 BOVET RD., SUITE 303, SAN MATEO
Vergleichen Sie SGMT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| SGMT | 4.36 | 148.74M | 0 | -29.25M | -22.80M | -1.1533 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Sagimet Biosciences Inc Aktie (SGMT) Neueste Nachrichten
Sagimet Biosciences keeps stock target with Buy rating on phase 3 program - Investing.com UK
Sagimet Biosciences presents clinical denifanstat, preclinical FASN inhibitor da - TipRanks
Sagimet Biosciences Presents Clinical Denifanstat and - GlobeNewswire
Sagimet's Denifanstat Shows 49% Fibrosis Improvement in Phase 2b MASH Trial | SGMT Stock News - StockTitan
Institutional investors in Sagimet Biosciences Inc. (NASDAQ:SGMT) see US$36m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance
Sagimet Biosciences (NASDAQ:SGMT) Earns "Buy" Rating from HC Wainwright - MarketBeat
Steven Cohen's Strategic Acquisition in Sagimet Biosciences Inc - GuruFocus.com
Hillhouse Capital Management's Strategic Reduction in Sagimet Bi - GuruFocus.com
Baker Bros. Advisors LP Increases Stake in Sagimet Biosciences I - GuruFocus.com
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives $24.00 Consensus Price Target from Analysts - Defense World
Sagimet Biosciences Advances MASH Treatment with Denifanstat - TipRanks
Sagimet: More Than Just A MASH Drug Development Biotech (NASDAQ:SGMT) - Seeking Alpha
Sagimet Biosciences reports Q3 EPS (45c) vs (35c) last year - TipRanks
Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
Sagimet Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Ascletis Completes Enrollment of Phase III Trial of ASC40 Once-Daily Oral Tablet for Treatment of Acne - Marketscreener.com
UBS says Sagimet stock could steal the MASH spotlight from injectables - Investing.com Canada
Sagimet stock draws buy at UBS on MASH(SGMT:NASDAQ) - Seeking Alpha
SGMTSagimet Biosciences Inc. Series A Latest Stock News & Market Updates - StockTitan
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Sagimet Biosciences (NASDAQ:SGMT) Coverage Initiated by Analysts at UBS Group - MarketBeat
Sagimet Biosciences initiated with a Buy at UBS - TipRanks
Sagimet Biosciences Insiders Benefit From Selling Stock At US$3.10 - Simply Wall St
Trend Tracker for (SGMT) - Stock Traders Daily
Sagimet Biosciences to Participate in the UBS Global Healthcare Conference - The Manila Times
Sagimet planning Phase 3 trials of denifanstat in MASH, MASLD - Liver Disease News
HC Wainwright Reaffirms "Buy" Rating for Sagimet Biosciences (NASDAQ:SGMT) - MarketBeat
Sagimet’s denifanstat enters Phase III trials for MASH treatment - Yahoo Finance
Sagimet Biosciences Announces Successful Completion of - GlobeNewswire
Sagimet Biosciences Announces Successful Completion of End-Of-Phase 2 Interactions with Fda on the Development of Denifanstat for Mash - Marketscreener.com
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024 - StockTitan
(SGMT) Technical Data - Stock Traders Daily
Sagimet Biosciences Inc. (NASDAQ:SGMT) Short Interest Update - MarketBeat
Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat - Seeking Alpha
(SGMT) Investment Analysis and Advice - Stock Traders Daily
There is no way Sagimet Biosciences Inc (SGMT) can keep these numbers up - SETE News
Market Highlights: Sagimet Biosciences Inc (SGMT) Ends on a Low Note at 5.13 - The Dwinnex
Sagimet Biosciences Announces Upcoming Presentations at AASLDThe Liver Meeting® 2024 - GlobeNewswire
How to interpret Sagimet Biosciences Inc (SGMT)’s stock chart patterns - US Post News
Sagimet Biosciences Inc’s Shares Reel: 42.19% Quarterly Revenue Decline Amid 167.12M Market Cap - The InvestChronicle
SGMT (Sagimet Biosciences Inc) may reap gains as insiders became active recently - Knox Daily
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in the Lancet Gastroenterology and Hepatology - Marketscreener.com
Sagimet Gains on Latest Numbers - Baystreet.ca
Sagimet's denifanstat shows promise in Phase 2b MASH trial - Investing.com
Sagimet's denifanstat shows promise in Phase 2b MASH trial By Investing.com - Investing.com UK
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial - The Bakersfield Californian
Sagimet Biosciences Announces Publication of Results from - GlobeNewswire
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology - StockTitan
Sagimet Biosciences Inc (SGMT) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Sagimet Biosciences Inc [SGMT] Shares Fall Approximately -47.47% Over the Year - Knox Daily
Financial Metrics Check: Sagimet Biosciences Inc (SGMT)’s Ratios for Trailing Twelve Months - The Dwinnex
Finanzdaten der Sagimet Biosciences Inc-Aktie (SGMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):